GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Mainz Biomed NV (NAS:MYNZ) » Definitions » Return-on-Tangible-Asset

MYNZ (Mainz Biomed NV) Return-on-Tangible-Asset : 0.00% (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Mainz Biomed NV Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Mainz Biomed NV's annualized Net Income for the quarter that ended in Dec. 2024 was $0.00 Mil. Mainz Biomed NV's average total tangible assets for the quarter that ended in Dec. 2024 was $7.73 Mil. Therefore, Mainz Biomed NV's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2024 was 0.00%.

The historical rank and industry rank for Mainz Biomed NV's Return-on-Tangible-Asset or its related term are showing as below:

MYNZ' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -218.22   Med: -168.67   Max: -84.52
Current: -125.35

During the past 6 years, Mainz Biomed NV's highest Return-on-Tangible-Asset was -84.52%. The lowest was -218.22%. And the median was -168.67%.

MYNZ's Return-on-Tangible-Asset is ranked worse than
88.89% of 225 companies
in the Medical Diagnostics & Research industry
Industry Median: -5.14 vs MYNZ: -125.35

Mainz Biomed NV Return-on-Tangible-Asset Historical Data

The historical data trend for Mainz Biomed NV's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mainz Biomed NV Return-on-Tangible-Asset Chart

Mainz Biomed NV Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Return-on-Tangible-Asset
Get a 7-Day Free Trial -84.52 -218.22 -174.28 -163.05 -194.75

Mainz Biomed NV Quarterly Data
Dec19 Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24 Dec24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -209.65 -167.74 -157.15 - -

Competitive Comparison of Mainz Biomed NV's Return-on-Tangible-Asset

For the Diagnostics & Research subindustry, Mainz Biomed NV's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mainz Biomed NV's Return-on-Tangible-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Mainz Biomed NV's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Mainz Biomed NV's Return-on-Tangible-Asset falls into.


;
;

Mainz Biomed NV Return-on-Tangible-Asset Calculation

Mainz Biomed NV's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=-21.651/( (12.014+10.221)/ 2 )
=-21.651/11.1175
=-194.75 %

Mainz Biomed NV's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2024 )  (Q: Jun. 2024 )(Q: Dec. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2024 )  (Q: Jun. 2024 )(Q: Dec. 2024 )
=0/( (5.248+10.221)/ 2 )
=0/7.7345
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2024) net income data.


Mainz Biomed NV  (NAS:MYNZ) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Mainz Biomed NV Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Mainz Biomed NV's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Mainz Biomed NV Business Description

Traded in Other Exchanges
N/A
Address
Robert Koch Strasse 50, Sirius Gutenberg Park, Mainz, RP, DEU, 55129
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.